GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
last added cars
Kite Pharma
Kite’s Yescarta Yields a Success in a Phase 3 Trial for Treating Large B-Cell Lymphoma
2023-03-22
Global Head of Research of Kite Pharma Unveiled the Key Elements to Success in Adoptive Cell Therapy
2023-03-07
Kite And Arcellx Join Forces for Developing Cell Therapy targeting Multiple Myeloma
2022-12-12
Kite to Use Refuge’s Gene Expression Platform for New CAR-T Therapies
2022-10-21
Kite’s Yescarta Climbs Up To Treat Second-Line B-Cell Lymphomas After EC Nod
2022-10-18
Bristol Myers Squibb Requests $1.2 Billion Patent Revival From Supreme Court
2022-06-17
AACR 2022: Raising Capital for Drugs of the Future- Cell Therapies
2022-04-18
Kite’s Yescarta – The First CAR-T Cell Therapy Approved for B cell Lymphoma
2022-04-06
Daiichi Sankyo Authorizes First Yescarta Treatment Site in Japan
2021-12-17
San Diego Startup Nabs $140 Million Following BeiGene, Kite Partnerships
2021-11-03
FDA Approves Kite’s CAR-T Therapy for Adult Leukemia
2021-10-04
Gilead’s Kite Wins Legal Battle Against BMS, Gets Its $1.2B Fine Overturned
2021-08-27
Kite to Invest in Next Generation Immunotherapy with Appia Bio Collaboration
2021-08-06
R&D
Gilead’s CAR-T Drug Outperforms Standard of Care in B-Cell Lymphoma Trial
2021-06-29
Day 1 ASCO 2021 Roundup: Combating Lung Cancer, Hematologic Malignancies and Advanced Solid Tumors
2021-06-05
1 2
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top